BioSpace News Archive

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today it is partnering with Translational Drug Development (TD2) as the contract research organization (CRO) to conduct the Phase 1 clinical development of lead drug candidate QN-302.

TFC Therapeutics (TFC), a biotechnology company focused on developing novel biologics to target and eliminate key drivers of cancer recurrence and metastasis, today announced a financing led by ARCH Venture Partners with participation from Breakout Ventures, Alexandria Real Estate Equities, and Alumni Ventures.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”) today announced the completion of its bioequivalence study of IkT-001Pro compared to 400 mg imatinib mesylate.

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the second quarter ended June 30, 2023.

FOXO Technologies Inc. (NYSEAM: FOXO), a leader in the field of commercializing epigenetic biomarker technology, has advanced in its mission to utilize the power of epigenetics and artificial intelligence to generate data-driven insights that promote optimal health and longevity.

3DCERAM Sinto, Inc. (3DCERAM Sinto Inc; https://sintoamerica.com/3dceram-sinto-usa/), a turnkey provider for additive manufacturing of advanced ceramics, and SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT; “SINTX” or the “Company”), a manufacturer of advanced ceramics for biomedical and technical markets, announced today a collaboration to develop multiple novel resins and processes for the additive manufacturing of ceramic products.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of a post-hoc analysis of the pivotal, Phase 3 study (MCI186-19) reviewing the effect of intravenous (IV) RADICAVA® (edaravone) on survival and additional disease progression milestone events in people with amyotrophic lateral sclerosis (ALS).

Quanta Dialysis Technologies® today announced that it has completed enrollment of its Home Run study for at-home hemodialysis.

Response Pharmaceuticals, Inc. today announced the successful completion of its Phase 1B clinical trial for the company’s lead drug candidate, RDX-002, a first-in-class inhibitor of intestinal microsomal triglyceride transfer protein (iMTP).

Marker Therapeutics (NASDAQ: MRKR) highlights its technology during a recently held, 75-minute Demi-Colton Virtual Salon/Webinar on cell therapy and CAR-T, a breakthrough cancer treatment that modifies a patient’s own T cells to fight cancer.